Aug 30, 2024
by Suyeon Jang
G2G Bio Passes Technical Evaluation for IPO – A Major Milestone
Hello everyone,
We’re excited to share some fantastic news from one of our Series C portfolio companies, G2G Bio.
The company has recently passed a critical technical evaluation, receiving strong ratings—Grade A from both NICE D&B and Korea Enterprise Data (KED). This marks a key step forward as the company moves toward a potential IPO through the technology-special listing track.
G2G Bio is developing innovative long-acting injectable formulations, and their technology is gaining attention globally—especially in the fast-growing obesity treatment market.
At the heart of their platform is a solution to extend the effects of GLP-1 receptor agonists like semaglutide, the active ingredient in widely used weight loss drugs such as Wegovy and Mounjaro. Currently, these treatments require weekly injections—but G2G Bio’s formulation may stretch that to once per month, potentially transforming the treatment experience for patients worldwide.
What is the “Technology-Special Listing” (Tech IPO) Process?
In Korea, the technology-special listing path allows early-stage companies to go public even without strong revenue, as long as they demonstrate exceptional technological value.
The process involves two main evaluations:
Technical Evaluation – This assesses the originality, feasibility, and future potential of the company’s core technologies.
Commercial Viability Review – This looks at how the technology could succeed in the actual market.
With the technical evaluation already passed, G2G Bio is now one step closer to IPO, having cleared half of the listing journey.
This is a milestone not only for G2G Bio, but also for Laplace Partners Venture Fund I, and we’re thrilled to share this progress with our community.
Back to News